Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSEAMERICAN:ARMP NYSE:DNA NASDAQ:IMMX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.81-2.1%$2.89$2.56▼$6.44$558.14M0.254.32 million shs2.61 million shsARMPArmata Pharmaceuticals$5.06+12.2%$6.86$2.32▼$16.34$165.57M1.26249,128 shs535,836 shsDNAGinkgo Bioworks$7.57-4.4%$8.81$5.37▼$17.58$516.72M1.771.11 million shs877,077 shsIMMXImmix Biopharma$8.80-14.1%$9.47$1.94▼$12.14$557.72M0.091.94 million shs3.91 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.09%-6.02%+4.07%-17.60%-31.13%ARMPArmata Pharmaceuticals+12.20%+27.46%-28.53%-65.81%+110.83%DNAGinkgo Bioworks-4.05%-16.64%-17.57%-8.05%-25.32%IMMXImmix Biopharma-14.15%-16.35%+0.92%-9.09%+196.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.81-2.1%$2.89$2.56▼$6.44$558.14M0.254.32 million shs2.61 million shsARMPArmata Pharmaceuticals$5.06+12.2%$6.86$2.32▼$16.34$165.57M1.26249,128 shs535,836 shsDNAGinkgo Bioworks$7.57-4.4%$8.81$5.37▼$17.58$516.72M1.771.11 million shs877,077 shsIMMXImmix Biopharma$8.80-14.1%$9.47$1.94▼$12.14$557.72M0.091.94 million shs3.91 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.09%-6.02%+4.07%-17.60%-31.13%ARMPArmata Pharmaceuticals+12.20%+27.46%-28.53%-65.81%+110.83%DNAGinkgo Bioworks-4.05%-16.64%-17.57%-8.05%-25.32%IMMXImmix Biopharma-14.15%-16.35%+0.92%-9.09%+196.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.70Moderate Buy$15.71459.23% UpsideARMPArmata Pharmaceuticals 2.67Moderate Buy$15.00196.44% UpsideDNAGinkgo Bioworks 1.67Reduce$8.5012.36% UpsideIMMXImmix Biopharma 2.67Moderate Buy$20.67134.85% UpsideCurrent Analyst Ratings BreakdownLatest ARMP, ALT, IMMX, and DNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026DNAGinkgo Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/18/2026IMMXImmix Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/18/2026IMMXImmix Biopharma Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/17/2026IMMXImmix Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$19.006/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/18/2026ARMPArmata Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K13,661.52N/AN/A$1.99 per share1.41ARMPArmata Pharmaceuticals$4.90M37.91N/AN/A($6.00) per share-0.84DNAGinkgo Bioworks$170.15M2.90N/AN/A$8.74 per share0.87IMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)ARMPArmata Pharmaceuticals-$173.80M-$1.64N/AN/AN/A-5,432.79%N/A-75.29%8/11/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)Latest ARMP, ALT, IMMX, and DNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026IMMXImmix Biopharma-$0.17N/AN/AN/AN/AN/A8/11/2026Q2 2026ALTAltimmune-$0.15N/AN/AN/A$0.00 millionN/A8/11/2026Q2 2026ARMPArmata Pharmaceuticals-$0.48N/AN/AN/A$0.40 millionN/A8/6/2026Q2 2026DNAGinkgo Bioworks-$0.8950N/AN/AN/A$24.05 millionN/A5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/13/2026Q1 2026ARMPArmata Pharmaceuticals-$0.38-$3.16-$2.78-$3.16$0.74 million$0.79 million5/7/2026Q1 2026DNAGinkgo Bioworks-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56ARMPArmata PharmaceuticalsN/A0.640.64DNAGinkgo BioworksN/A5.155.15IMMXImmix BiopharmaN/A8.758.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ARMPArmata Pharmaceuticals3.57%DNAGinkgo Bioworks78.63%IMMXImmix Biopharma11.26%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%ARMPArmata Pharmaceuticals84.50%DNAGinkgo Bioworks12.69%IMMXImmix Biopharma30.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableARMPArmata Pharmaceuticals7036.71 million5.69 millionNot OptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableARMP, ALT, IMMX, and DNA HeadlinesRecent News About These CompaniesIMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & ...4 hours ago | caledonianrecord.comCIMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.4 hours ago | enidnews.comEIMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.July 20 at 5:33 PM | globenewswire.comImmix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud ClaimsJuly 20 at 12:13 PM | newsfilecorp.comNIMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the FirmJuly 20 at 11:47 AM | globenewswire.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 98.6% in JuneJuly 16, 2026 | marketbeat.comLGT Fund Management Co Ltd. Acquires 291,594 Shares of Immix Biopharma, Inc. $IMMXJuly 13, 2026 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 12, 2026 | marketbeat.comWhy Immix Biopharma, Inc.’s (IMMX) Stock Is Up 10.10%July 7, 2026 | aaii.comAAll You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to BuyJune 24, 2026 | zacks.comWall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a BetJune 18, 2026 | zacks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)May 28, 2026 | theglobeandmail.comWall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?May 27, 2026 | zacks.comImmix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common StockMay 22, 2026 | quiverquant.comQImmix Biopharma Announces Closing of $150 Million Underwritten Offering of Common StockMay 22, 2026 | globenewswire.comImmix rises after mid-stage trial data for AL amyloidosis therapyMay 21, 2026 | seekingalpha.comWhat's going on with Immix Biopharma stock Thursday?May 21, 2026 | msn.comImmix Biopharma Reports 95% Complete Response Rate in NEXICART-2 Trial for AL Amyloidosis PatientsMay 21, 2026 | quiverquant.comQImmix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common StockMay 21, 2026 | globenewswire.comImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2May 21, 2026 | globenewswire.comIs Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?May 5, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026The AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 20263 Overlooked Tech ETFs That Are Quietly Killing It This YearBy Nathan Reiff | June 27, 2026ARMP, ALT, IMMX, and DNA Company DescriptionsAltimmune NASDAQ:ALT$2.81 -0.06 (-2.09%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$2.81 0.00 (0.00%) As of 07/20/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Armata Pharmaceuticals NYSEAMERICAN:ARMP$5.06 +0.55 (+12.20%) Closing price 07/20/2026 04:10 PM EasternExtended Trading$4.87 -0.19 (-3.83%) As of 07/20/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Ginkgo Bioworks NYSE:DNA$7.56 -0.35 (-4.36%) Closing price 07/20/2026 03:59 PM EasternExtended Trading$7.59 +0.02 (+0.33%) As of 07/20/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Immix Biopharma NASDAQ:IMMX$8.80 -1.45 (-14.15%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$8.86 +0.06 (+0.72%) As of 07/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Why Gold Miners Could Be the Market's Biggest Comeback Story A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
